ISPE updates and expands guidance for testing of GxP systems

Published: 17-Jan-2013
Regulatory

Conforms to GAMP 5 concepts and terminology


The International Society for Pharmaceutical Engineering (ISPE), a US authority on best practices for the pharmaceutical industry, has issued updated and expanded guidance to help pharmaceutical companies maximise testing efficiency of computerised and software-based systems that affect patient safety, product quality and data integrity.

The second edition of the GAMP Testing Guide has been revised to conform with GAMP 5 concepts and terminology and reflect ICH Q8, Q9 and Q10, Quality by Design (QbD) and Process Analytical Technology principles. It has also been expanded to include information on cloud computing, automated testing and non-linear development.

‘We have aimed this guide at anyone who has ever worried that their testing is not sufficiently focused on the real risks to patient safety or wondered whether they might be doing too much or too little testing,’ said Karen Ashworth, who co-led the industry group responsible for producing the guidance.

‘The guide offers practical advice on how to use risk assessment to define the correct scope of testing and on how to avoid costly duplication of testing that has already been done by a supplier or at an earlier phase of the system lifecycle.’

The ISPE GAMP Good Practice Guide: A Risk-Based Approach to Testing of GxP Systems (Second Edition) encourages regulated pharmaceutical companies and their suppliers to work together to ensure sufficient test coverage to prove that systems are fit for their intended use and minimise duplicated effort. It also provides answers as to which system elements should be tested, why they should be tested, how much testing is necessary and how tests should be conducted and documented.

The guide is available for purchase on the ISPE website.

  • Companies:
  • International Society for Pharmaceutical Engineering
See more

You may also like

Regulatory

PDA and ISPE publish guide to finding root cause of quality failure

Read more
The organisations have also announced that they have signed a MOU confirming their plans to continue to advance practical approaches for quality culture

Trending Articles

  1. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

PDA and ISPE publish guide to finding root cause of quality failure

The organisations have also announced that they have signed a MOU confirming their plans to continue to advance practical approaches for quality culture
Regulatory

ISPE releases the new Cultural Excellence Report

Report concentrates on Leadership and Vision, Mindset and Attitudes, Gemba Walk, Leading Quality Indicators and Triggers, Oversight and Review and Structural Enablers
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Complex drugs take up more QA resource

Quality Assurance not only requires increasing resource but also needs to be introduced at an increasingly early stage of development. Susan Birks reports on trends, regulatory changes and issues affecting quality programmes
Regulatory

ISPE launches plan to prevent drug shortages

Experts collaborate to help keep quality medicines available to those who need them
Regulatory

ISPE releases first look at its plan to prevent drug shortages

Aimed at helping the pharmaceutical industry avoid drug shortages and maintain a robust and reliable supply of medications to patients world-wide
Packaging

ISPE releases guidance for standardising use of booklet labels

To help companies conducting clinical trials in multiple countries
Regulatory

ISPE updates water and steam systems guide

Addresses changes to industrial practices and global regulations
Subscribe now